Skip to main content

Table 1 Patient and disease characteristics

From: Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy

Characteristic

N (%)

Characteristic

N (%)

Age (years)

 

ER/PR status

81 (100)

Mean (SD)

65.6 (10.58)

ER-positive

80 (98.77)

Median (range)

66 (36–82)

ER-negative

1 (1.23)

  

PR-positive

51 (62.96)

Stage at diagnosis

 

PR-negative

4 (4.94)

Stage 1

36 (44.44)

PR-unknown

26 (32.10)

Stage 2

45 (55.56)

  
  

HER2 status

 
  

HER2-positive

Histology

 

HER2-negative

81 (100)

Ductal invasive

36 (44.44)

  

Lobular invasive

36 (44.44)

Ki67 status (%)

 

Others

9 (11.12)

Mean (SD)

26.76 (20.44)

  

Median (range)

25 (3–90)

Tumor size

 

Ki67 < 15%

22 (27.16)

≤ 20 mm

34 (41.98)

Ki67 ≥ 15%

29 (35.80)

20–30 mm

37 (45.68)

Ki67 unknown

30 (37.04)

>  30 mm

9 (11.11)

  

Unknown

1 (1.23)

uPA (ng/mg of protein)

 
  

Mean (SD)

4.37 (3.9)

Tumor grade

 

Median (range)

3 (0.1–18.7)

Grade 1

11 (13.58)

uPA ≤ 3

41 (50.62)

Grade 2

67 (82.72)

uPA >  3

40 (49.38)

Grade 3

3 (3.70)

  
  

PAI-1 (ng/mg of protein)

 

Nodal status

 

Mean (SD)

21.47 (18.89)

Node-negative

75 (92.59)

Median (range)

16 (0–140)

Node-positive

PAI-1 ≤ 14

32 (39.51)

Unknowna

5 (6.17)

PAI-1 >  14

49 (60.49)

  

uPA and PAI-1 combinations

 
  

uPA ≤ 3 and PAI-1 ≤ 14

30 (37.04)

  

uPA ≤ 3 and PAI-1 >  14

11 (13.58)

  

uPA > 3 and PAI-1 ≤ 14

2 (2.47)

  

uPA > 3 and PAI-1 > 14

38 (46.91)

  1. aAll clinically node-negative